Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Puma Biotechnology Stock Shoves It in Short Sellers' Faces

Biotech stocks are not for the faint of heart by any stretch of the imagination. Puma Biotechnology (NYSE: PBYI  )  has repeatedly shown the investing world why this is the case, and today's 200% plus movement upward should drive this point home. 

PBYI Chart

PBYI data by YCharts

After soaring by over 350% last year, Puma has fallen hard in recent months due to a mysterious case of investor pessimism for its cancer drug PB272, aka neratinib. Specifically, Puma shares cratered by 25% in a single day after the company earlier this year announced partial midstage trial results for neratinib as a potential treatment for breast cancer that has spread to the brain.

What bummed investors out apparently was that neratinib produced severe diarrhea in a number of patients participating in the study. As I mentioned previously, I found this panic selling to be overdone at the time, largely because neratinib's undesirable side-effect profile was known prior to the company licensing the drug from Pfizer (NYSE: PFE  ) . Moreover, this particular type of adverse effect (NYSE: PFE  ) can be managed effectively through the proactive use of antidiarrheals, and Puma has taken the steps to do so in its ongoing trials.  

Pfizer turns pessimistic, makes a stunningly bad business decision 
The investing community was apparently not alone in thinking that neratinib's commercial potential was overblown. Pfizer this week amended its licensing agreement with Puma for neratinib, pushing the bulk of clinical trial expenses onto Puma and giving up a nice chunk of potential royalty payments in the process.

Per the new agreement, Puma is now responsible for funding the ongoing legacy trials for neratinib, which will substantially increase the company's expenses moving forward. By the same token, Pfizer is now only entitled to a percentage of royalties on net sales in the low to mid teens (previously up to 20%).

Puma has the last laugh
Almost immediately after announcing this amended agreement, Puma on Tuesday released top-line data from a late-stage study for neratinib as a treatment for HER2-positive breast cancer. According to the release, patients receiving neratinib showed a whopping 33% increase in disease-free survival, or DFS, compared to placebo. The company plans on filing for regulatory approval in early 2015.

Neratinib would enter a market that already sports a megablockbuster in Roche's Herceptin. Although neratinib's exact role in the clinic for early stage HER2-positive breast cancer patients remains to be seen, the drug's path toward blockbuster status certainly became a lot easier after Puma posted these strong trial results.

Foolish wrap-up
I think the market and Pfizer's combined pessimism stemmed mainly from the failure of GlaxoSmithKline's drug Tykerb to significantly improve DFS in its late-stage trial for HER2-positive breast cancer patients in an adjuvant setting. Indeed, a number of drugs have failed to outperform Herceptin for this indication, and neratinib looked like it was going to be the next victim. Now that neratinib has shown to improve clinical outcomes for HER2-positive patients in a large late-stage study, it should become an important part of the breast cancer pharma landscape. Which of course begs the question as to whether Puma therefore could be a prime takeover target. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 3040153, ~/Articles/ArticleHandler.aspx, 9/5/2015 10:44:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

George Budwell

George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Today's Market

updated 13 hours ago Sponsored by:
DOW 16,102.38 -272.38 -1.66%
S&P 500 1,921.22 -29.91 -1.53%
NASD 4,683.92 -49.58 -1.05%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/4/2015 4:01 PM
PBYI $90.15 Down -0.38 -0.42%
Puma Biotechnology… CAPS Rating: *
PFE $31.37 Down -0.52 -1.63%
Pfizer CAPS Rating: ****